bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
bold words at #ims22 on last slide: based on griffin, not only quad d-vrd but also d-r maintenance should be considered standard of care! these mrd neg slides are the most interesting in my mind. clearly dara-r is flipping more pts to mrd-neg than rev alone 
Asst Professor @UWMedicine @fredhutch, s/p @UCSFCancer heme/onc ?? CAR-T training. #MMsm #TcellRx #cellphonesandcelltherapies ????

COI: https://t.co/3Uuojuio6R